ACR 2026 Daily Podcasts - Day3b Save
Can a smartphone identify inflammatory arthritis
Can Gut Candida Trigger Rheumatoid Arthritis Maybe
CAR T Without Lymphodepletion
First theranostic approach to treat difficult-to-treat RA
Lifestyle Interventions and Biological Effects in RA
New Rheumatic Disease after CAR-T
Pain in axSpA may Reflect More than Inflammation
Preliminary PK, PD, Clinical and Safety Data of NK019 in Myositis
Real World of SARD ILD
Use of JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease
VALORous Efforts in Dermatomyositis Interstitial Lung Disease
Who Manages Fibromyalgia
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow Live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to RheumNow.live to see the full program and register today.
Hi.
This is Bella Mehta from RheumNow reporting from ACR twenty six. And this is a very interesting abstract on the 08/1869 that I found. And this is looking at if if just hand photographs from any smartphone can identify synovitis. I mean, isn't that the key question in rheumatology? Can can some...
Can there be an easy reproducible way to figure out if patients have swelling? What these people did is got a thousand patients' ordinary hand photographs taken from a smartphone and compared it with joint counts from a rheumatologist as well as ultrasound. And the sensitivity was 80%, specificity of 70%, and the negative predictive value was around 98%. So and this will help find a fusion, and there was a robust external validation, especially with the study. And when we use ultrasound defined synovitis as a reference instead of the joint counts only, the sensitivity did increase to around 89%.
So now with computer vision and AI getting these pictures from ordinary, know, day to day life, we have... You know, we can now diagnose these patients or at least get them the right help even early on. So, you know, these could be patients who have a rule out inflammatory arthritis even before they actually reach a doctor. So, again, this will help reshape rheumatology, I think, if we can do this right and can do this in practice long term. So with that, signing off, this is Bella Mehta from RheumNow.
Follow me on Twitter, Bella underscore Mehta. Thank you. Hi.
I'm doctor Janet Pope. I'm a rheumatologist and professor of medicine at Western University, London, Canada. I tweet as at Janet Bourdeaux, and I'm here as part of the RheumNow group, covering the meeting, ACR twenty twenty six in sunny Orlando, Florida. I wanted to talk about, an oral presentation abstract number two eight three two, and I thought it was one of our best abstracts of today so far. So the idea is we know the microbiome is perturbed in just about any autoimmune disease, probably almost any disease, by treatment, by inflammation, by other things that might increase the chance of getting a disease.
So the question here was could Candida albicans trigger rheumatoid arthritis? And this was out of the Denver group, and they have the early RA cohort. They also have the RA at risk patients, and they were able to do all that kind of look as well as looking in a mouse model. So first of all, candida albicans can be increased in the microbiome of patients with RA and at risk RA, and this group showed it. Also, we know in the gut that IgA for candida albicans and some other candida can be increased in these patients.
So sort of a link that something's going on compared to controls. Also, if they looked at a mouse model and they gave Candida, to change the gut microbiome, it in and of itself was insufficient to cause inflammatory arthritis for the, mice that would be bred to be at risk for RA. But the idea was it could be silent immune priming to increase the risk of, inflammatory arthritis if something else occurs, maybe an infection, maybe a trauma, etc. So what they found was that in the mice they didn't get inflammatory arthritis until they were primed for something else after, but the Th17 pathway was altered. They had very eloquent studies saying that if they blocked it, things would improve.
If they, upregulated it, it would worsen. So why did I choose this? First of all, I think there's probably almost as high as our microbiome of the number of studies of, the differences in patients with RA versus healthy controls. I chose it because I do think patients ask, you know, what causes, number one. But number two, more importantly, could we intervene earlier to try to make a healthy gut microbiome for our at risk RA patients that maybe they wouldn't develop RA or for our RA patients who...
And whom we're trying to treat to a target and they're not reaching it. So hopefully more will come in this field of research. I think the presentation was was very well done. Please follow us at RheumNow. Thank
David Lu here as part of RheumNow's ACR convergence twenty twenty six coverage. It's all happening in sunny Orlando, and we just want to kind of raise one thing that's, really caught my eye. There's a lot of CAR T development, program data that's coming out. As you'd imagine, a lot of relatively small studies are bursting through but in amongst that they're not all the same and actually what we're seeing is a little bit of innovation and really trying to target some of the pain points that come up with CAR T. Now I guess if you think about CAR T as really arduous and manufactured traditionally that you know you take a couple of weeks to prepare stuff you need to keep people in keep them there for some time as part of the delivery process.
They need substantial lymphodepletion and that's where a lot of the risk is and then they then we get problems after that potentially as well inflammatory problems after that very broadly speaking, then a lot of these things are getting, chipped away at in terms of the way we do things. So one really cool thing that I saw out there was, the allo three twenty nine product. And this is a CAR T that doesn't just target CD19, but also CD70. And CD70 is important here because actually it's on host lymphocytes that are activated to attack donor cells. So inbuilt in this CAR T is not just what it's meant to actually do, but an active anti rejection mechanism.
What does that mean? Well, what they're doing in the study is they're testing it to see whether you can use it without lymphodepletion and still get the same outcomes. So some patients are getting lymphodepletion, but looking at the patients that aren't getting lymphodepletion, these are scleroderma patients by the way, and you can actually see that they're getting good clinical outcomes just the same as the cyclophosphamide patients, the fludarabine and cyclophosphamide patients as well and the lymphodepletion patients small numbers, a couple of them, but they seem to be doing just as well with this CD19, CD70 targeting. And in fact, well, you can see that they get a modest transient B cell drop of maybe about 25% for the first couple of months but they don't get the really devastating lymphodepletion that we see with other therapies that we need with other therapies, and the actual therapy efficacy seems to stick. Now, I mean, this is one of many abstracts out there which are doing interesting things.
Another one that I saw, this Alacardi off the shelf with limited lymphodepletion is doing all of this as a day procedure. We're at the point where things are getting pretty safe for certain types of CAR T in the first initial bit. So why do we need to keep them in hospital? Well, actually, this is what they're pushing the boundaries of as well. There's a lot of other really interesting stuff like that as a as a as this whole therapeutic area evolves just in the way that things evolve for TNF inhibitors, they're evolving for CAR T, and it's really exciting to see that play out.
So for plenty more about this CAR T journey, you know where to go. Roomnow.com.
Hello. I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting for RheumNow at ACR Convergence twenty twenty six in Orlando, Florida. Today, I have Peter Mandel and Gregor Mitter from the University of Vienna School of Medicine who've been presenting a very interesting poster about the use of fibroblast activation protein inhibitor coupled to lutetium, a radio labeled nucleotide or a nuclide to target the fibroblasts in rheumatoid arthritis synovian and treat active rheumatoid arthritis that's been resistant to other conventional therapies. So Peter, Gregor, tell us a little bit about what you found.
Yeah. So we had two patients, one with RA and one with PSA, who were difficult to treat with a long standing story of multiple drug failure. We tried to make this approach, which has been known to oncology, to inject intravenously fibroblast activation protein inhibitor coupled with lutetium. And we saw quite good results in decrease of C. Diffeile, swollen joint count, tender joint count in both patients.
So this is very interesting. And Peter, you're targeting tissue resident fibroblasts. It's very difficult to target fibroblasts because unlike circulating t cells or b cells, these are in the synovium. How did you come up with this novel idea to take this approach?
So as Greg already mentioned, this approach is already used. This compound is already used in oncology, where the idea is, of course, to target, bring the, the lutetium is a beta emitter, so it's a systemic radio ligand therapy. In our case, there the idea is that it would, because each tumor has a fibroblast environment or structure around it, that it would bring thereby the emitter within the vicinity of the tumor cells. In our case, this would be in a way analogous to radio synovial or thesis where we would inject it into a single joint. But in our case, we give this systemically.
And we do see, we saw very, you know, in our diagnostic studies, we do see high uptake of of the the gallium label so that the diagnostic FAPI, in the synovial joints of patients, the two patients, Gregor mentioned, with with difficult to treat one with RA and the other one PSA.
So this is a targeted approach going back to the... Probably twenty, thirty years ago using yttrium injected into the joint in a nonspecific way of ablating the inflamed synovium. But here, you're using a targeted agent to target those fibroblasts that are probably pathogenic in the synovium.
Yes. It it... As analogy, this is not napalm bombing a forest, but a... If if if you may, a targeted intervention of a certain species of plants.
So this is fantastic. Where do you see this going? You've treated two patients. One with so called difficult to treat rheumatoid arthritis, another with multidrug experience psoriatic arthritis. What are your current plans for further development?
So obviously we want to take this forward and treat more patients. So what we've seen importantly is we saw both in a decrease in the standardized uptake values on the follow-up PET if we did that. We also did sinus biopsies of these patients before and after the treatment and saw a reduction in the number of fat positive expressing fibroblasts. And we did see, particularly in the RA patient, a steady reduction of disease activity.
So this is wonderful. So this is now a new era of targeted therapies, but using radionuclide instead of antibodies or other protein derived drugs to treat difficult to treat rheumatoid arthritis and other forms of inflammatory arthritis. For more information about this and other topics, please go to roomnow.com. I'm Jonathan Kaye with Peter Mandel and Gregor Mitter here at ACR Convergence twenty twenty six. See you again soon.
Thanks.
Hi, everyone. Jack Cush, ACR twenty twenty six Orlando, live in the room now booth where there's been a lot of action, a lot of significant teachers and, learners sharing their information with you at this meeting. I've been a bit overwhelmed, but what I... But about what I've seen. I want to talk to you about something I saw this morning.
The lead presentation at the plenary session, twenty eight zero three is the abstract number. Hannah McClellan from the Duke University School of Medicine, the Molecular Physiology Institute. I think I think had a fabulous presentation on the impact of lifestyle interventions, in older adults with rheumatoid arthritis looking specifically at immune signaling. So we can imagine that's gonna work, right, clinically and give some kind of benefit to people. But are there immunologic correlates to what happens with lifestyle intervention?
What we're talking about here is, especially as RA patients get older, sarcopenia is a problem at least twenty five percent. Patients get weaker, and getting weaker, they do less, they do less, they hurt more, they hurt more, they do less. It's a spiral down. Right? I always try to get my older patients with RA to make their number one goal getting strong.
If you get strong, things get better. And that's what they did in this trial. The trial was called sweat and chat. And what they did was... It's a sixteen week trial of older RA patients.
They're seropositive, and they are randomized to either sixteen weeks of two visits about diet, exercise, counseling, then, and that's the CHAT cohort, the control cohort. The active intervention cohort is the SWET cohort, s w e t by the way, where they get regular ongoing aerobic and resistance exercise training, where they're aiming at a hundred and fifty minutes, a week and, that along with dietary interventions. Then doing a readout on that at the end of the study period. The results were pretty dramatic. So they did get better with the intervention and the clinical improvement was shown significant clinical improvement in dash 28 CRP, in swollen joint count, and patient global assessments were all significant.
Sed rate and CRP, not significant. Interestingly, cytokines across the board, no change. But cellular subset analysis done by facts showed significant decreases in Treg cells, in CD four PD one cells, in CD four memory cells, and NK cells across the board for the people that had the active intervention, lifestyle intervention of diet and vigorous exercise. As I said, a plethora of, metabolic and cytokine, readouts showed no significance. And then they went on to show a lot of correlation with these biologic findings with clinical effects and you have to look at the abstract to really see, what that...
All that meant. In the end, they showed that very clearly that the lifestyle intervention led to, a modulation of lymphocyte profiling. Okay? And basically changed patients from... As far as their strength, their tone, their RA activity, changed them from, you know, sort of a failing older patient to someone whose biology was that of a younger patient.
And the net result is that, you know, lymphocytes, disease activity and muscle properties were greatly enhanced by the lifestyle intervention. This was a pilot trial. Right? So there's only twenty people that that had the intervention. But I think it's strong data about what we should be doing and certainly a call for more information about lifestyle interventions and what the benefits are gonna be in rheumatoid arthritis.
Tune in for more, RheumNow.
David Lu here as part of RheumNow's coverage of ACR twenty twenty six. It's been a big meeting. I just wanted to bring you some of the CAR T content, something that caught my eye. It was actually a poster, from the Mayo. Looking at something that's come up before, which is this idea that maybe we might get these...
New rheumatic disease after CAR T. We might get immune related adverse events after CAR T. Now there's been a Spanish report about some of this a while back. Obviously, we have limited our numbers in terms of rheumatic or autoimmune disease CAR T. But in oncology, they've been using CAR T for some time or more years than us.
And so actually, this is the opportunity to look back and see how they've gone. Have they... Those patients developed, immune related adverse events, new rheumatic disease? So this Mayo, cohort looked at thirteen thirty five conventional, CAR T patients and looked to see what the rates were from that. So out of those, seventeen developed new onset autoimmune disease.
So that's one point two seven. The previous Spanish estimate was, just below two percent. So really in that same ballpark. So not a massive number, certainly a lot less than what you see with immune checkpoint inhibitors. And I think critically as well, when you break that down, about half of them were the non ICANS immune mediated neurotoxicity.
So, but neurotoxicity, so not our classic rheumatic diseases. When you break it down out of those thirteen thirty five, when you break down to the seventeen, saw four had sarcoid, four had a seronegative inflammatory arthritis, one each in PMR and GCA. So in amongst that, you know, causality is always really hard to determine in these situations. I think as well, even though thirteen thirty five sounds like a lot of patients when you're getting these relatively rare things, It's very hard to determine patterns of of of what are still small numbers. But we're really seeing something which is very different to immune checkpoint inhibitors.
You know, this might be all part of, guess, expansion, cell population expansion in CAR T and that might be driving it. But fundamentally, it's a lot less phenotypic. It's a lot less structured. It's something which is not the same and is a lot less common than immune checkpoint inhibitors. It's not the same.
It's a... It's definitely a much more dispersed phenotype, and I don't think it's gonna be as much of a problem by many orders of magnitude compared to immune checkpoint inhibitors and immune related adverse events there. So for plenty more on our CAR T content, you know where to go. Rheumnow.com.
Hi everybody, this is Adela Castro reporting from Orlando here at ACR twenty twenty six, and I want to discuss about the importance of identifying nociplastic pain in patients with asthma. The first abstract that I'm going to be discussing is number thirteen thirty two, and it evaluated the symptom burden, disease activity, and brain connectivity in a cohort of asthma patients. Interestingly, in this cohort, eighty four percent of the patients did not have evidence of inflammation in spite of having all disease activity and this importance of brain connectivity. So these findings definitely highlight the importance of altered brain connectivity in pain amplification in patients with asthma. On that same note, I want to present abstract thirteen fifty four, which evaluated the presence of and the impact of fibromyalgia symptoms in patients from an Indian cohort that also had asthma.
And in this patient population, included one hundred and fifty one patients out of which, you know, it was a very low prevalence for fibromyalgia syndrome. However, it still showed that in spite of having, in spite of evaluating the pain, it also found that patients had more worsening of their outcomes in terms of disease activity, quality of life, and symptom burden. So definitely it's very important to keep in mind when evaluating patients with asthma, not only evaluate about their disease activity, but take into account other components that can affect their pain, including nocciplastic pain. Well, for more, follow-up with us in room now.
Hello, my name is Doctor. Guillermo Valenzuela. I'm a rheumatologist and being happy to broadcast from here from the ACR twenty twenty six. Thank you to RheumNow for giving me the chance to give you this update on the preliminary data on the NKX019 in patients with myositis. This data that I will be discussing is preliminary data from the cohort of the patients in the ENTRAS-two study.
The study is a phase one, II that uses NKX019 as the agent. NKX019 is an engineered CAR NK cell that expresses CD19 with affinity for the B cell receptor CD19. In addition, there is another modification to the construct that includes membrane bound IL-fifteen which is known to increase the killing power of the NK cell as well as the stability in the site of action. The cell is, allogeneic, it is cryopreserved and has the characteristics and the benefits of a off the shelf treatment that can be provided as an outpatient setting. In fact, 20 patients in this cohort of 20 that I will be presenting today were patients that were administered the treatment in the outpatient setting.
Another important characteristic of this, cell is that, it has predictable PK which has allowed us to, increase the doses in incremental fashion, based on the area under the curve which expresses its maximum benefit. As a matter of the study design, these patients received, initial consent. I must say also that all the patients in this clinical trial are patients with myositis with refractory disease. Patients received, as I said, consent. They underwent early conditioning chemotherapy with Fludarabine and cyclophosphamide for three consecutive days and then they receive the NKX019 in three subsequent days.
The data that I presented represents the three different cohorts, the one billion, two billion and four billion exploratory doses. There's also a regimen that we'll be exploring which is with four billion cells at days zero, two and four to maximize the area under the curve in the Cmax. The outcomes were clinical characteristics of the patients, PKPD and also safety. Now, the results show that in terms of metrics, five out of six patients achieved a TIS score of moderate to major in their responses. The results in terms of the muscle strength on MM8, again five out of six patients achieved major responses and the patients who had component of cutaneous manifestations, fifty percent of them showed improvement and the other half maintained their responses.
In terms of safety, the most important thing in this cohort of patients with difficult to treat myositis with an NK cell which is off the shelf and administered in the outpatient setting is that the patients do not need to stay overnight for treatment. None of the patients underwent a cytokine release syndrome or a graft versus host disease or an immune mediated cell event or I can't. No reported deaths were either in this study. So all the data that I presented certainly support the need for further exploration of NKX019 in patients with myositis. With that, I would like to thank you for your attention and I hope to continue to follow us in the next presentation about safety on the same subject.
Thank you.
Hello, everyone. I'm Richard Conway from Dublin, Ireland, reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an interesting poster from Sunday's poster session. This was abstract number four seventy. It was by Matute Gallardo and colleagues from Spain.
This was titled Treatment Patterns of Oral ILD Compared to Other Autoimmune ILDs. I'm calling it the real world of SARD ILD treatment. And I guess people are going to think I'm banging on about the same thing endlessly, but this interested me because it shows what rheumatologists in Spain, not in The US, but in Spain, do in practice and how that contrasts with the ACR, SARD, ILD guidelines. So just a way of background, the ACR guidelines recommend for rheumatoid arthritis related interstitial lung disease three first line therapies. But in order of preference, mycophenolate mofetil first, azathioprine second, rituximab third.
So these authors reported from their patient population about how these patients were actually treated in clinical practice. So they had patients with oral ILD and patients with other rheumatic diseases associated with ILD. They had eighty five patients in total, thirty eight of those had rheumatoid arthritis related interstitial lung disease. So the non rheumatoid arthritis patients first, of the usual stuff, systemic sclerosis, IPAF, some other autoimmune diseases associated with lung disease. And in that group, largely speaking, mycophenolate mofetol was the preferred option being seen for the various indications, somewhere between seventy five percent, eighty five percent of patients were on mycophenolate.
So that kind of matches both the ACR guidelines for those diseases and matches what I do in clinical practice and I think most rheumatologists do. But where the contrast came was with RA ILD. So again, remember ACR guidelines, mycophenolate number one, azatyper number two, rituximab number three. So first thing, I was delighted to see this, ninety five percent of those RA patients were on methotrexate despite the fact that they had ILD. So obviously there is confidence in the data that says it is safe and if anything may be beneficial to some extent in RAILD.
And then when they got down into the advanced therapies, what they found, so patients on mycophenolate mofetil, zero. Patients on azathioprine, zero. Most commonly used medication, abatacept, twenty six percent of patients on that. Sixteen percent on rituximab, sixteen percent on tocilizumab, sixteen percent on nothing other than the methotrexate, which can be reasonable. And then the remainder were on a variety of JAK inhibitors and TNF inhibitors.
So why do I like this abstract? I think, like anybody, I like when it supports your own clinical practice. And it seems that all those doubting thoughts that the ACR guidelines generate of, am I actually way out of sync with everyone, is not true. And that's in reality, most rheumatologists are managing rheumatoid arthritis related interstitial lung disease as I manage it, which is treating the rheumatoid arthritis with our best rheumatoid arthritis medications. And that is where we go.
So I've been Richard Conway. Follow me on Twitter at RichardPAconway for more from ACR twenty twenty six from me and check out RheumNow for all the best ACR 2026.
Hello. My name is Elena Jerns and I'm reporting from Orlando, Florida. A lot of interest in JAK inhibitors in RA ILD at this meeting. I'm glad to see the studies because we certainly need more. It does seem that JAK inhibitors are helpful in RA ILD based on a small meta analysis which was published in 2024.
But we have so many JAK inhibitors now and we are often limited by insurance companies in what we can prescribe. But are they truly interchangeable? Are they truly safe and efficacious in ILD? Well, this meeting had several relevant posters. So poster number four seventy eight by Doctor.
Munoz detailed results of a retrospective observational study of baricitinib in eighty four patients with RA ILD. They demonstrated stability of PFTs and improvement in dyspnea throughout follow-up, and importantly the steroid use was decreased. We of course don't know how their trajectory was prior to the treatment from the abstract, but the improvement in symptoms and reduction in steroids is encouraging regardless. Poster number four forty nine by Doctor. Kikuchi and colleagues also demonstrated that the array ILD was stable and even improved based on lung ultrasound scores with JAK inhibitors.
They didn't specify the JAK inhibitors, unfortunately. In poster seven zero three, Doctor. Ortiz and colleagues looked at 43 patients from Spain treated with upadacitinib and found stability or improvement in lung function parameters and again symptoms of dyspnea. Despite these promising results, JAK inhibitors are still not widely used in
our
RAYALDEE as per poster number four sixty two by Doctor. Sarmiento Monroy regarding real world treatment patterns in RAILD. Their nested case control study from Spain showed that only three percent of patients with RAILD were treated with JAK inhibitors, but eleven percent of patients with RA with no ILD at baseline were treated with JAK inhibitors. Important safety signal for JAK inhibitor was accessed. I think the worry about cardiovascular safety precludes us often from prescribing JAK inhibitors in RA ALD, as these patients are frequently dosed with many cardiovascular risk factors also.
Poster number four forty one by Doctor. Kasiraj compared safety between JAK inhibitors and found that tofacitinib was associated with significantly higher risk compared to upadacitinib or baricitinib in terms of major cardiovascular events. And Doctor. Kazuo's study in poster four forty two found that signal as well tofacitinib but not upadacitinib was associated with higher risk of major cardiovascular events in a real world study. The multitude of studies of JAK inhibitors, and these are not even all the posters about them, support the use of JAK inhibitors in RYLD.
Safety signals support going for baricitinib upotacitinib in patients with RAYLD who have cardiovascular risk factors. And I would advocate for perhaps a randomized controlled trial in specifically RAYLD using specific JAK inhibitors. It does seem like we're not using JAK inhibitors enough in our ILD yet, but hopefully it'll change with more data. Thank you. Hi.
I'm Derek Mueller, PA from Detroit, Michigan, and I'm here at ACR twenty twenty six in Orlando, Florida. And what I'd like to talk to you about today is Valoris efforts in dermatomyositis interstitial lung disease. So we know that interstitial lung disease is a major comorbidity in inflammatory myopathies. Dermatomyositis is no exception. And I wanna talk about abstract number one five eight six, which is a sub analysis of the VALOR trial, which was the pivotal study that got brepocitinib approved for the treatment in patients with dermatomyositis.
Now patients with interstitial lung disease were not excluded from this trial, and the sub analysis looked at the twenty percent of patients with ILD, in in this trial who were enrolled and and specifically aimed to look at outcomes of dermatomyositis patients with and without ILD in that sub analysis. The efficacy endpoints looking at total improvement score in the patients with and without interstitial lung disease were actually quite comparable. So it didn't seem like that was necessarily a a factor in efficacy of muscle domain endpoints. There was also very similar steroid sparing efficacy looking at ILD patients without... With and without ILD patients with and without ILD.
Now there's definitely some big time caveats here given that this is a sub analysis and it's a relatively small population of ILD patients nestled within the, within the VALOR trial. VALOR was never powered to rigorously assess and evaluate DM ILD patients. Also, the the ILD in these patients was relatively mild. The median FVC was seventy seven point five percent. And just for a frame of reference, normal FVC, is is greater than 80, so relatively mild.
So key takeaways here that there was demonstrated efficacy in these muscle domain specific endpoints in DM patients with and without ILD. And it didn't seem like steroid use or the steroid sparing was an issue even in these patients with ILD. They demonstrated, similar outcomes with steroid sparing. So the ILD was not necessarily driving the the prescription and escalation of steroids here. And then some other caveats just to wait...
Take away too that in this population, in the VALOR trial, patients were not excluded if they were on a background conventional, agent. So patients, in the setting of ILD or just DM in general, they could still continue, their their mycophenolate, and such if they were if they were on that, on a stable dose at enrollment. So just think about that when when you consider this trial as well. So what this means to me is that we should consider brefacitinib in DM patients with or without ILD, but I think this is a call to action to better understand the therapies that we have our disposal and the impact that they may have on patients with dermatomyositis related interstitial lung disease.
Hello, and welcome to ACR Convergence with RheumNow. My name is Eric Dine from Summit, New Jersey, and I'm here to talk about fibromyalgia at this conference. Abstract fifteen fifty four was presented, during the poster session where they talked about some shifting perceptions, amongst rheumatologists, between the years 2012 and today in 2026. The the... This was a survey specifically, conducted in Ontario, so reflective of of, their local rheumatology community of, community and academic rheumatologists.
Over the last fourteen years from 2012 to today, there is an increasing recognition that fibromyalgia is a severe disabling disease with fifty eight percent of respondents responding to the survey in 2012 stating that they felt that it was disabling. That number fifty eight percent went up to seventy one percent in the most recent survey. But despite this idea that fibromyalgia is severe and disabling, there was less acceptance that it is a rheumatic disease and should be managed by rheumatologists. And that fell pretty starkly over that fourteen year period. Almost a third of respondents in 2012 said that they felt rheumatology had ownership of it.
Seven percent said that in the most recent. Would they accept a new referral for fibromyalgia? Sixty sixty percent in 2012. That came down to under a quarter, twenty four percent in the most recent study. So the idea being fibromyalgia is significant, but it's not in our domain is what most rheumatologists responded, in these surveys.
So who does have ownership of it? Who should be the primary physician managing it? That has changed in the survey. So in 2012, eighty nine percent felt it was in the domain of family medicine or primary care. In the more recent study, that dropped from eighty nine percent to thirty nine percent with a rise of chronic pain physicians, being the predominant physicians that were felt to be the cause with fifty two percent, being the physician, that was identified being the chronic pain.
So the idea coming from this is that rheumatologists, at least in this sample of Ontario, rheumatologists felt that fibromyalgia is something that is significant, it is disabling, but it's not rheumatic. But unfortunately, I'm not sure that's what primary care or pain doctors still continue to send them to rheumatology. And unfortunately, these patients get lost looking for physicians to help care for them, it's a very prevalent common disorder. It's a little bit disappointing for me to see that there is less acceptance of it amongst rheumatologists and such a stark decrease. So I think that is something that is important that we help coordinate pathways amongst multiple physicians between sleep doctors, primary care doctors, psychiatry, pain management, rheumatology to work on on getting the appropriate care for these patients.
So a little disappointing for me to see that that number has declined so much, but hopeful that we as a team amongst physicians can help care for these patients. For more information at ACR Convergence, tune in to RheumNow.
Go to RheumNow.live to see the full program and register today.
Hi.
This is Bella Mehta from RheumNow reporting from ACR twenty six. And this is a very interesting abstract on the 08/1869 that I found. And this is looking at if if just hand photographs from any smartphone can identify synovitis. I mean, isn't that the key question in rheumatology? Can can some...
Can there be an easy reproducible way to figure out if patients have swelling? What these people did is got a thousand patients' ordinary hand photographs taken from a smartphone and compared it with joint counts from a rheumatologist as well as ultrasound. And the sensitivity was 80%, specificity of 70%, and the negative predictive value was around 98%. So and this will help find a fusion, and there was a robust external validation, especially with the study. And when we use ultrasound defined synovitis as a reference instead of the joint counts only, the sensitivity did increase to around 89%.
So now with computer vision and AI getting these pictures from ordinary, know, day to day life, we have... You know, we can now diagnose these patients or at least get them the right help even early on. So, you know, these could be patients who have a rule out inflammatory arthritis even before they actually reach a doctor. So, again, this will help reshape rheumatology, I think, if we can do this right and can do this in practice long term. So with that, signing off, this is Bella Mehta from RheumNow.
Follow me on Twitter, Bella underscore Mehta. Thank you. Hi.
I'm doctor Janet Pope. I'm a rheumatologist and professor of medicine at Western University, London, Canada. I tweet as at Janet Bourdeaux, and I'm here as part of the RheumNow group, covering the meeting, ACR twenty twenty six in sunny Orlando, Florida. I wanted to talk about, an oral presentation abstract number two eight three two, and I thought it was one of our best abstracts of today so far. So the idea is we know the microbiome is perturbed in just about any autoimmune disease, probably almost any disease, by treatment, by inflammation, by other things that might increase the chance of getting a disease.
So the question here was could Candida albicans trigger rheumatoid arthritis? And this was out of the Denver group, and they have the early RA cohort. They also have the RA at risk patients, and they were able to do all that kind of look as well as looking in a mouse model. So first of all, candida albicans can be increased in the microbiome of patients with RA and at risk RA, and this group showed it. Also, we know in the gut that IgA for candida albicans and some other candida can be increased in these patients.
So sort of a link that something's going on compared to controls. Also, if they looked at a mouse model and they gave Candida, to change the gut microbiome, it in and of itself was insufficient to cause inflammatory arthritis for the, mice that would be bred to be at risk for RA. But the idea was it could be silent immune priming to increase the risk of, inflammatory arthritis if something else occurs, maybe an infection, maybe a trauma, etc. So what they found was that in the mice they didn't get inflammatory arthritis until they were primed for something else after, but the Th17 pathway was altered. They had very eloquent studies saying that if they blocked it, things would improve.
If they, upregulated it, it would worsen. So why did I choose this? First of all, I think there's probably almost as high as our microbiome of the number of studies of, the differences in patients with RA versus healthy controls. I chose it because I do think patients ask, you know, what causes, number one. But number two, more importantly, could we intervene earlier to try to make a healthy gut microbiome for our at risk RA patients that maybe they wouldn't develop RA or for our RA patients who...
And whom we're trying to treat to a target and they're not reaching it. So hopefully more will come in this field of research. I think the presentation was was very well done. Please follow us at RheumNow. Thank
David Lu here as part of RheumNow's ACR convergence twenty twenty six coverage. It's all happening in sunny Orlando, and we just want to kind of raise one thing that's, really caught my eye. There's a lot of CAR T development, program data that's coming out. As you'd imagine, a lot of relatively small studies are bursting through but in amongst that they're not all the same and actually what we're seeing is a little bit of innovation and really trying to target some of the pain points that come up with CAR T. Now I guess if you think about CAR T as really arduous and manufactured traditionally that you know you take a couple of weeks to prepare stuff you need to keep people in keep them there for some time as part of the delivery process.
They need substantial lymphodepletion and that's where a lot of the risk is and then they then we get problems after that potentially as well inflammatory problems after that very broadly speaking, then a lot of these things are getting, chipped away at in terms of the way we do things. So one really cool thing that I saw out there was, the allo three twenty nine product. And this is a CAR T that doesn't just target CD19, but also CD70. And CD70 is important here because actually it's on host lymphocytes that are activated to attack donor cells. So inbuilt in this CAR T is not just what it's meant to actually do, but an active anti rejection mechanism.
What does that mean? Well, what they're doing in the study is they're testing it to see whether you can use it without lymphodepletion and still get the same outcomes. So some patients are getting lymphodepletion, but looking at the patients that aren't getting lymphodepletion, these are scleroderma patients by the way, and you can actually see that they're getting good clinical outcomes just the same as the cyclophosphamide patients, the fludarabine and cyclophosphamide patients as well and the lymphodepletion patients small numbers, a couple of them, but they seem to be doing just as well with this CD19, CD70 targeting. And in fact, well, you can see that they get a modest transient B cell drop of maybe about 25% for the first couple of months but they don't get the really devastating lymphodepletion that we see with other therapies that we need with other therapies, and the actual therapy efficacy seems to stick. Now, I mean, this is one of many abstracts out there which are doing interesting things.
Another one that I saw, this Alacardi off the shelf with limited lymphodepletion is doing all of this as a day procedure. We're at the point where things are getting pretty safe for certain types of CAR T in the first initial bit. So why do we need to keep them in hospital? Well, actually, this is what they're pushing the boundaries of as well. There's a lot of other really interesting stuff like that as a as a as this whole therapeutic area evolves just in the way that things evolve for TNF inhibitors, they're evolving for CAR T, and it's really exciting to see that play out.
So for plenty more about this CAR T journey, you know where to go. Roomnow.com.
Hello. I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting for RheumNow at ACR Convergence twenty twenty six in Orlando, Florida. Today, I have Peter Mandel and Gregor Mitter from the University of Vienna School of Medicine who've been presenting a very interesting poster about the use of fibroblast activation protein inhibitor coupled to lutetium, a radio labeled nucleotide or a nuclide to target the fibroblasts in rheumatoid arthritis synovian and treat active rheumatoid arthritis that's been resistant to other conventional therapies. So Peter, Gregor, tell us a little bit about what you found.
Yeah. So we had two patients, one with RA and one with PSA, who were difficult to treat with a long standing story of multiple drug failure. We tried to make this approach, which has been known to oncology, to inject intravenously fibroblast activation protein inhibitor coupled with lutetium. And we saw quite good results in decrease of C. Diffeile, swollen joint count, tender joint count in both patients.
So this is very interesting. And Peter, you're targeting tissue resident fibroblasts. It's very difficult to target fibroblasts because unlike circulating t cells or b cells, these are in the synovium. How did you come up with this novel idea to take this approach?
So as Greg already mentioned, this approach is already used. This compound is already used in oncology, where the idea is, of course, to target, bring the, the lutetium is a beta emitter, so it's a systemic radio ligand therapy. In our case, there the idea is that it would, because each tumor has a fibroblast environment or structure around it, that it would bring thereby the emitter within the vicinity of the tumor cells. In our case, this would be in a way analogous to radio synovial or thesis where we would inject it into a single joint. But in our case, we give this systemically.
And we do see, we saw very, you know, in our diagnostic studies, we do see high uptake of of the the gallium label so that the diagnostic FAPI, in the synovial joints of patients, the two patients, Gregor mentioned, with with difficult to treat one with RA and the other one PSA.
So this is a targeted approach going back to the... Probably twenty, thirty years ago using yttrium injected into the joint in a nonspecific way of ablating the inflamed synovium. But here, you're using a targeted agent to target those fibroblasts that are probably pathogenic in the synovium.
Yes. It it... As analogy, this is not napalm bombing a forest, but a... If if if you may, a targeted intervention of a certain species of plants.
So this is fantastic. Where do you see this going? You've treated two patients. One with so called difficult to treat rheumatoid arthritis, another with multidrug experience psoriatic arthritis. What are your current plans for further development?
So obviously we want to take this forward and treat more patients. So what we've seen importantly is we saw both in a decrease in the standardized uptake values on the follow-up PET if we did that. We also did sinus biopsies of these patients before and after the treatment and saw a reduction in the number of fat positive expressing fibroblasts. And we did see, particularly in the RA patient, a steady reduction of disease activity.
So this is wonderful. So this is now a new era of targeted therapies, but using radionuclide instead of antibodies or other protein derived drugs to treat difficult to treat rheumatoid arthritis and other forms of inflammatory arthritis. For more information about this and other topics, please go to roomnow.com. I'm Jonathan Kaye with Peter Mandel and Gregor Mitter here at ACR Convergence twenty twenty six. See you again soon.
Thanks.
Hi, everyone. Jack Cush, ACR twenty twenty six Orlando, live in the room now booth where there's been a lot of action, a lot of significant teachers and, learners sharing their information with you at this meeting. I've been a bit overwhelmed, but what I... But about what I've seen. I want to talk to you about something I saw this morning.
The lead presentation at the plenary session, twenty eight zero three is the abstract number. Hannah McClellan from the Duke University School of Medicine, the Molecular Physiology Institute. I think I think had a fabulous presentation on the impact of lifestyle interventions, in older adults with rheumatoid arthritis looking specifically at immune signaling. So we can imagine that's gonna work, right, clinically and give some kind of benefit to people. But are there immunologic correlates to what happens with lifestyle intervention?
What we're talking about here is, especially as RA patients get older, sarcopenia is a problem at least twenty five percent. Patients get weaker, and getting weaker, they do less, they do less, they hurt more, they hurt more, they do less. It's a spiral down. Right? I always try to get my older patients with RA to make their number one goal getting strong.
If you get strong, things get better. And that's what they did in this trial. The trial was called sweat and chat. And what they did was... It's a sixteen week trial of older RA patients.
They're seropositive, and they are randomized to either sixteen weeks of two visits about diet, exercise, counseling, then, and that's the CHAT cohort, the control cohort. The active intervention cohort is the SWET cohort, s w e t by the way, where they get regular ongoing aerobic and resistance exercise training, where they're aiming at a hundred and fifty minutes, a week and, that along with dietary interventions. Then doing a readout on that at the end of the study period. The results were pretty dramatic. So they did get better with the intervention and the clinical improvement was shown significant clinical improvement in dash 28 CRP, in swollen joint count, and patient global assessments were all significant.
Sed rate and CRP, not significant. Interestingly, cytokines across the board, no change. But cellular subset analysis done by facts showed significant decreases in Treg cells, in CD four PD one cells, in CD four memory cells, and NK cells across the board for the people that had the active intervention, lifestyle intervention of diet and vigorous exercise. As I said, a plethora of, metabolic and cytokine, readouts showed no significance. And then they went on to show a lot of correlation with these biologic findings with clinical effects and you have to look at the abstract to really see, what that...
All that meant. In the end, they showed that very clearly that the lifestyle intervention led to, a modulation of lymphocyte profiling. Okay? And basically changed patients from... As far as their strength, their tone, their RA activity, changed them from, you know, sort of a failing older patient to someone whose biology was that of a younger patient.
And the net result is that, you know, lymphocytes, disease activity and muscle properties were greatly enhanced by the lifestyle intervention. This was a pilot trial. Right? So there's only twenty people that that had the intervention. But I think it's strong data about what we should be doing and certainly a call for more information about lifestyle interventions and what the benefits are gonna be in rheumatoid arthritis.
Tune in for more, RheumNow.
David Lu here as part of RheumNow's coverage of ACR twenty twenty six. It's been a big meeting. I just wanted to bring you some of the CAR T content, something that caught my eye. It was actually a poster, from the Mayo. Looking at something that's come up before, which is this idea that maybe we might get these...
New rheumatic disease after CAR T. We might get immune related adverse events after CAR T. Now there's been a Spanish report about some of this a while back. Obviously, we have limited our numbers in terms of rheumatic or autoimmune disease CAR T. But in oncology, they've been using CAR T for some time or more years than us.
And so actually, this is the opportunity to look back and see how they've gone. Have they... Those patients developed, immune related adverse events, new rheumatic disease? So this Mayo, cohort looked at thirteen thirty five conventional, CAR T patients and looked to see what the rates were from that. So out of those, seventeen developed new onset autoimmune disease.
So that's one point two seven. The previous Spanish estimate was, just below two percent. So really in that same ballpark. So not a massive number, certainly a lot less than what you see with immune checkpoint inhibitors. And I think critically as well, when you break that down, about half of them were the non ICANS immune mediated neurotoxicity.
So, but neurotoxicity, so not our classic rheumatic diseases. When you break it down out of those thirteen thirty five, when you break down to the seventeen, saw four had sarcoid, four had a seronegative inflammatory arthritis, one each in PMR and GCA. So in amongst that, you know, causality is always really hard to determine in these situations. I think as well, even though thirteen thirty five sounds like a lot of patients when you're getting these relatively rare things, It's very hard to determine patterns of of of what are still small numbers. But we're really seeing something which is very different to immune checkpoint inhibitors.
You know, this might be all part of, guess, expansion, cell population expansion in CAR T and that might be driving it. But fundamentally, it's a lot less phenotypic. It's a lot less structured. It's something which is not the same and is a lot less common than immune checkpoint inhibitors. It's not the same.
It's a... It's definitely a much more dispersed phenotype, and I don't think it's gonna be as much of a problem by many orders of magnitude compared to immune checkpoint inhibitors and immune related adverse events there. So for plenty more on our CAR T content, you know where to go. Rheumnow.com.
Hi everybody, this is Adela Castro reporting from Orlando here at ACR twenty twenty six, and I want to discuss about the importance of identifying nociplastic pain in patients with asthma. The first abstract that I'm going to be discussing is number thirteen thirty two, and it evaluated the symptom burden, disease activity, and brain connectivity in a cohort of asthma patients. Interestingly, in this cohort, eighty four percent of the patients did not have evidence of inflammation in spite of having all disease activity and this importance of brain connectivity. So these findings definitely highlight the importance of altered brain connectivity in pain amplification in patients with asthma. On that same note, I want to present abstract thirteen fifty four, which evaluated the presence of and the impact of fibromyalgia symptoms in patients from an Indian cohort that also had asthma.
And in this patient population, included one hundred and fifty one patients out of which, you know, it was a very low prevalence for fibromyalgia syndrome. However, it still showed that in spite of having, in spite of evaluating the pain, it also found that patients had more worsening of their outcomes in terms of disease activity, quality of life, and symptom burden. So definitely it's very important to keep in mind when evaluating patients with asthma, not only evaluate about their disease activity, but take into account other components that can affect their pain, including nocciplastic pain. Well, for more, follow-up with us in room now.
Hello, my name is Doctor. Guillermo Valenzuela. I'm a rheumatologist and being happy to broadcast from here from the ACR twenty twenty six. Thank you to RheumNow for giving me the chance to give you this update on the preliminary data on the NKX019 in patients with myositis. This data that I will be discussing is preliminary data from the cohort of the patients in the ENTRAS-two study.
The study is a phase one, II that uses NKX019 as the agent. NKX019 is an engineered CAR NK cell that expresses CD19 with affinity for the B cell receptor CD19. In addition, there is another modification to the construct that includes membrane bound IL-fifteen which is known to increase the killing power of the NK cell as well as the stability in the site of action. The cell is, allogeneic, it is cryopreserved and has the characteristics and the benefits of a off the shelf treatment that can be provided as an outpatient setting. In fact, 20 patients in this cohort of 20 that I will be presenting today were patients that were administered the treatment in the outpatient setting.
Another important characteristic of this, cell is that, it has predictable PK which has allowed us to, increase the doses in incremental fashion, based on the area under the curve which expresses its maximum benefit. As a matter of the study design, these patients received, initial consent. I must say also that all the patients in this clinical trial are patients with myositis with refractory disease. Patients received, as I said, consent. They underwent early conditioning chemotherapy with Fludarabine and cyclophosphamide for three consecutive days and then they receive the NKX019 in three subsequent days.
The data that I presented represents the three different cohorts, the one billion, two billion and four billion exploratory doses. There's also a regimen that we'll be exploring which is with four billion cells at days zero, two and four to maximize the area under the curve in the Cmax. The outcomes were clinical characteristics of the patients, PKPD and also safety. Now, the results show that in terms of metrics, five out of six patients achieved a TIS score of moderate to major in their responses. The results in terms of the muscle strength on MM8, again five out of six patients achieved major responses and the patients who had component of cutaneous manifestations, fifty percent of them showed improvement and the other half maintained their responses.
In terms of safety, the most important thing in this cohort of patients with difficult to treat myositis with an NK cell which is off the shelf and administered in the outpatient setting is that the patients do not need to stay overnight for treatment. None of the patients underwent a cytokine release syndrome or a graft versus host disease or an immune mediated cell event or I can't. No reported deaths were either in this study. So all the data that I presented certainly support the need for further exploration of NKX019 in patients with myositis. With that, I would like to thank you for your attention and I hope to continue to follow us in the next presentation about safety on the same subject.
Thank you.
Hello, everyone. I'm Richard Conway from Dublin, Ireland, reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an interesting poster from Sunday's poster session. This was abstract number four seventy. It was by Matute Gallardo and colleagues from Spain.
This was titled Treatment Patterns of Oral ILD Compared to Other Autoimmune ILDs. I'm calling it the real world of SARD ILD treatment. And I guess people are going to think I'm banging on about the same thing endlessly, but this interested me because it shows what rheumatologists in Spain, not in The US, but in Spain, do in practice and how that contrasts with the ACR, SARD, ILD guidelines. So just a way of background, the ACR guidelines recommend for rheumatoid arthritis related interstitial lung disease three first line therapies. But in order of preference, mycophenolate mofetil first, azathioprine second, rituximab third.
So these authors reported from their patient population about how these patients were actually treated in clinical practice. So they had patients with oral ILD and patients with other rheumatic diseases associated with ILD. They had eighty five patients in total, thirty eight of those had rheumatoid arthritis related interstitial lung disease. So the non rheumatoid arthritis patients first, of the usual stuff, systemic sclerosis, IPAF, some other autoimmune diseases associated with lung disease. And in that group, largely speaking, mycophenolate mofetol was the preferred option being seen for the various indications, somewhere between seventy five percent, eighty five percent of patients were on mycophenolate.
So that kind of matches both the ACR guidelines for those diseases and matches what I do in clinical practice and I think most rheumatologists do. But where the contrast came was with RA ILD. So again, remember ACR guidelines, mycophenolate number one, azatyper number two, rituximab number three. So first thing, I was delighted to see this, ninety five percent of those RA patients were on methotrexate despite the fact that they had ILD. So obviously there is confidence in the data that says it is safe and if anything may be beneficial to some extent in RAILD.
And then when they got down into the advanced therapies, what they found, so patients on mycophenolate mofetil, zero. Patients on azathioprine, zero. Most commonly used medication, abatacept, twenty six percent of patients on that. Sixteen percent on rituximab, sixteen percent on tocilizumab, sixteen percent on nothing other than the methotrexate, which can be reasonable. And then the remainder were on a variety of JAK inhibitors and TNF inhibitors.
So why do I like this abstract? I think, like anybody, I like when it supports your own clinical practice. And it seems that all those doubting thoughts that the ACR guidelines generate of, am I actually way out of sync with everyone, is not true. And that's in reality, most rheumatologists are managing rheumatoid arthritis related interstitial lung disease as I manage it, which is treating the rheumatoid arthritis with our best rheumatoid arthritis medications. And that is where we go.
So I've been Richard Conway. Follow me on Twitter at RichardPAconway for more from ACR twenty twenty six from me and check out RheumNow for all the best ACR 2026.
Hello. My name is Elena Jerns and I'm reporting from Orlando, Florida. A lot of interest in JAK inhibitors in RA ILD at this meeting. I'm glad to see the studies because we certainly need more. It does seem that JAK inhibitors are helpful in RA ILD based on a small meta analysis which was published in 2024.
But we have so many JAK inhibitors now and we are often limited by insurance companies in what we can prescribe. But are they truly interchangeable? Are they truly safe and efficacious in ILD? Well, this meeting had several relevant posters. So poster number four seventy eight by Doctor.
Munoz detailed results of a retrospective observational study of baricitinib in eighty four patients with RA ILD. They demonstrated stability of PFTs and improvement in dyspnea throughout follow-up, and importantly the steroid use was decreased. We of course don't know how their trajectory was prior to the treatment from the abstract, but the improvement in symptoms and reduction in steroids is encouraging regardless. Poster number four forty nine by Doctor. Kikuchi and colleagues also demonstrated that the array ILD was stable and even improved based on lung ultrasound scores with JAK inhibitors.
They didn't specify the JAK inhibitors, unfortunately. In poster seven zero three, Doctor. Ortiz and colleagues looked at 43 patients from Spain treated with upadacitinib and found stability or improvement in lung function parameters and again symptoms of dyspnea. Despite these promising results, JAK inhibitors are still not widely used in
our
RAYALDEE as per poster number four sixty two by Doctor. Sarmiento Monroy regarding real world treatment patterns in RAILD. Their nested case control study from Spain showed that only three percent of patients with RAILD were treated with JAK inhibitors, but eleven percent of patients with RA with no ILD at baseline were treated with JAK inhibitors. Important safety signal for JAK inhibitor was accessed. I think the worry about cardiovascular safety precludes us often from prescribing JAK inhibitors in RA ALD, as these patients are frequently dosed with many cardiovascular risk factors also.
Poster number four forty one by Doctor. Kasiraj compared safety between JAK inhibitors and found that tofacitinib was associated with significantly higher risk compared to upadacitinib or baricitinib in terms of major cardiovascular events. And Doctor. Kazuo's study in poster four forty two found that signal as well tofacitinib but not upadacitinib was associated with higher risk of major cardiovascular events in a real world study. The multitude of studies of JAK inhibitors, and these are not even all the posters about them, support the use of JAK inhibitors in RYLD.
Safety signals support going for baricitinib upotacitinib in patients with RAYLD who have cardiovascular risk factors. And I would advocate for perhaps a randomized controlled trial in specifically RAYLD using specific JAK inhibitors. It does seem like we're not using JAK inhibitors enough in our ILD yet, but hopefully it'll change with more data. Thank you. Hi.
I'm Derek Mueller, PA from Detroit, Michigan, and I'm here at ACR twenty twenty six in Orlando, Florida. And what I'd like to talk to you about today is Valoris efforts in dermatomyositis interstitial lung disease. So we know that interstitial lung disease is a major comorbidity in inflammatory myopathies. Dermatomyositis is no exception. And I wanna talk about abstract number one five eight six, which is a sub analysis of the VALOR trial, which was the pivotal study that got brepocitinib approved for the treatment in patients with dermatomyositis.
Now patients with interstitial lung disease were not excluded from this trial, and the sub analysis looked at the twenty percent of patients with ILD, in in this trial who were enrolled and and specifically aimed to look at outcomes of dermatomyositis patients with and without ILD in that sub analysis. The efficacy endpoints looking at total improvement score in the patients with and without interstitial lung disease were actually quite comparable. So it didn't seem like that was necessarily a a factor in efficacy of muscle domain endpoints. There was also very similar steroid sparing efficacy looking at ILD patients without... With and without ILD patients with and without ILD.
Now there's definitely some big time caveats here given that this is a sub analysis and it's a relatively small population of ILD patients nestled within the, within the VALOR trial. VALOR was never powered to rigorously assess and evaluate DM ILD patients. Also, the the ILD in these patients was relatively mild. The median FVC was seventy seven point five percent. And just for a frame of reference, normal FVC, is is greater than 80, so relatively mild.
So key takeaways here that there was demonstrated efficacy in these muscle domain specific endpoints in DM patients with and without ILD. And it didn't seem like steroid use or the steroid sparing was an issue even in these patients with ILD. They demonstrated, similar outcomes with steroid sparing. So the ILD was not necessarily driving the the prescription and escalation of steroids here. And then some other caveats just to wait...
Take away too that in this population, in the VALOR trial, patients were not excluded if they were on a background conventional, agent. So patients, in the setting of ILD or just DM in general, they could still continue, their their mycophenolate, and such if they were if they were on that, on a stable dose at enrollment. So just think about that when when you consider this trial as well. So what this means to me is that we should consider brefacitinib in DM patients with or without ILD, but I think this is a call to action to better understand the therapies that we have our disposal and the impact that they may have on patients with dermatomyositis related interstitial lung disease.
Hello, and welcome to ACR Convergence with RheumNow. My name is Eric Dine from Summit, New Jersey, and I'm here to talk about fibromyalgia at this conference. Abstract fifteen fifty four was presented, during the poster session where they talked about some shifting perceptions, amongst rheumatologists, between the years 2012 and today in 2026. The the... This was a survey specifically, conducted in Ontario, so reflective of of, their local rheumatology community of, community and academic rheumatologists.
Over the last fourteen years from 2012 to today, there is an increasing recognition that fibromyalgia is a severe disabling disease with fifty eight percent of respondents responding to the survey in 2012 stating that they felt that it was disabling. That number fifty eight percent went up to seventy one percent in the most recent survey. But despite this idea that fibromyalgia is severe and disabling, there was less acceptance that it is a rheumatic disease and should be managed by rheumatologists. And that fell pretty starkly over that fourteen year period. Almost a third of respondents in 2012 said that they felt rheumatology had ownership of it.
Seven percent said that in the most recent. Would they accept a new referral for fibromyalgia? Sixty sixty percent in 2012. That came down to under a quarter, twenty four percent in the most recent study. So the idea being fibromyalgia is significant, but it's not in our domain is what most rheumatologists responded, in these surveys.
So who does have ownership of it? Who should be the primary physician managing it? That has changed in the survey. So in 2012, eighty nine percent felt it was in the domain of family medicine or primary care. In the more recent study, that dropped from eighty nine percent to thirty nine percent with a rise of chronic pain physicians, being the predominant physicians that were felt to be the cause with fifty two percent, being the physician, that was identified being the chronic pain.
So the idea coming from this is that rheumatologists, at least in this sample of Ontario, rheumatologists felt that fibromyalgia is something that is significant, it is disabling, but it's not rheumatic. But unfortunately, I'm not sure that's what primary care or pain doctors still continue to send them to rheumatology. And unfortunately, these patients get lost looking for physicians to help care for them, it's a very prevalent common disorder. It's a little bit disappointing for me to see that there is less acceptance of it amongst rheumatologists and such a stark decrease. So I think that is something that is important that we help coordinate pathways amongst multiple physicians between sleep doctors, primary care doctors, psychiatry, pain management, rheumatology to work on on getting the appropriate care for these patients.
So a little disappointing for me to see that that number has declined so much, but hopeful that we as a team amongst physicians can help care for these patients. For more information at ACR Convergence, tune in to RheumNow.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.